demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only
metastatic/advanced mGC or mGEJC
mGC or mGEJC - M - HER2 neg/PDL1 positive
immune chekpoint inhibitors
anti-PD-(L)1
avelumab based treatment
avelumab alone JAVELIN Gastric 100 ...